2024-03-11 23:14:04 ET
Vertex Pharmaceuticals Incorporated (VRTX)
Leerink Partners Global Biopharma Conference Call
March 11, 2024 16:00 ET
Company Participants
Charlie Wagner - Executive Vice President & Chief Financial Officer
David Altshuler - Chief Scientific Officer
Conference Call Participants
David Risinger - Leerink Partners
Presentation
David Risinger
Good afternoon, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners [ph]. Two members of the Vertex leadership team; immediately to my left is Chief Scientific Officer, David Altshuler and to his left is CFO, Charlie Wagner. So I wanted to thank them for coming in from Boston to be with us here today. And obviously, the company has had tremendous momentum and delivered some very compelling data. So once again, thank you for taking the time. I know that you have a lot more work ahead as well.
Why don't we start with pain? It'd be great to hear what you're hearing from the field, what perspectives physicians are sharing with you on VX-548?
Charlie Wagner
Listen, David, thanks for hosting us today. We appreciate the opportunity. And maybe before I dive into that [indiscernible] mentioned the great data. We have had quite an exciting 100 days or so since early December. We've announced multiple regulatory approvals for CASGEVY. We released data in our Phase II DPN trial, data on our Phase III acute pain trial, data in our Phase III vanza trial in CF reported in the fourth quarter and gave guidance for the year....
Read the full article on Seeking Alpha
For further details see:
Vertex Pharmaceuticals Incorporated (VRTX) Leerink Partners Global Biopharma Conference (Transcript)